AbbVie stock up 1.3% after announcing resolution to litigation over Humira in the U.S.

Shares of AbbVie Inc. rose 1.3% in premarket trade Tuseday after the company announced it had resolved its litigation with biosimilar drugmaker Boehringer Ingelheim over U.S. patents for the rheumatoid arthritis drug Humira.